Sign up here for GlobalData's free bi-weekly Covid-19 report on the latest information your industry needs to know.The Coalition for Epidemic Preparedness Innovations (CEPI) has expanded its collaboration with China-based Sichuan Clover Biopharmaceuticals to speed-up the development and manufacture of Covid-19 vaccine candidate.
Clover’s S-Trimer vaccine candidate is based on its Trimer-Tag vaccine platform. In April, CEPI agreed to provide $3.5m funding support to prepare and launch a Phase I trial of Clover’s vaccine.
As part of the expanded alliance, CEPI will provide an additional $66m upfront for immediate funding of preclinical studies, to carry out Phase I clinical trials and prepare sites worldwide for an efficacy trial.